Benitec Biopharma Announces Its Interim Data From BB-301 Phase 1b/2a Trial Shows Continued Durable Enhancements In Participants Treated With Low Dose Of BB-301; 100% Response Rate Seen Across All Patients Treated

Loading news article.

Benitec Biopharma Announces Its Interim Data From BB-301 Phase 1b/2a Trial Shows Continued Durable Enhancements In Participants Treated With Low Dose Of BB-301; 100% Response Rate Seen Across All Patients Treated | WAPE

Benitec Biopharma Announces Its Interim Data From BB-301 Phase 1b/2a Trial Shows Continued Durable Enhancements In Participants Treated With Low Dose Of BB-301; 100% Response Rate Seen Across All Patients Treated

Article summary

Related companies

Analyzed by WAPE AI.

Comments —